Share Email Print
cover

Proceedings Paper

Surface-enhancement Raman scattering of urine for prostate cancer risk assessment (Conference Presentation)

Paper Abstract

Prostate cancer is a heterogenous disease that has a varied range from indolent to highly aggressiveness. The routinely used biomarker, Prostate Specific Antigen (PSA), is controversial due to over-diagnosis. A new approach is urgently needed to discriminate the indolent and lethal prostate cancer. We report the measurements of patient urine using surface-enhancement Raman scattering (SERS) as a potential means of differentiating aggressive and indolent prostate cancer types. To this end, urine samples from twenty prostate cancer patients with known clinical outcome are investigated in this study, with ten in each of the two groups: aggressive and indolent. SERS measurements, ten for each sample, are carried out in blind without revealing any clinical details to the investigators. Principal component analysis (PCA) and linear discriminant analysis (LDA) are used to statistically analyze the large number of Raman spectra to identify and classify the specific Raman features potentially associated with aggressive and indolent prostate cancer types. The experimental classifications are compared with the clinical outcome of the prostate cancer patients to demonstration the potential of SERS as an alternative method for patient screening and decision-making for the optimal treatment strategy.

Paper Details

Date Published: 4 March 2019
PDF
Proc. SPIE 10891, Nanoscale Imaging, Sensing, and Actuation for Biomedical Applications XVI, 1089111 (4 March 2019); doi: 10.1117/12.2510265
Show Author Affiliations
Yiwei Ma, Stevens Institute of Technology (United States)
Liu Kai, Stevens Institute of Technology (United States)
Isaac Y. Kim, Rutgers Cancer Institute of New Jersey (United States)
Henry Du, Stevens Institute of Technology (United States)


Published in SPIE Proceedings Vol. 10891:
Nanoscale Imaging, Sensing, and Actuation for Biomedical Applications XVI
Dan V. Nicolau; Dror Fixler; Ewa M. Goldys, Editor(s)

© SPIE. Terms of Use
Back to Top
PREMIUM CONTENT
Sign in to read the full article
Create a free SPIE account to get access to
premium articles and original research
Forgot your username?
close_icon_gray